Literature DB >> 10777217

Tumor-derived mutations within the DNA-binding domain of p53 that phenotypically resemble the deletion of the proline-rich domain.

J Roth1, P Koch, A Contente, M Dobbelstein.   

Abstract

The p53 tumor suppressor protein induces apoptosis through a mechanism that may involve the transcriptional activation of cellular genes, including the PIG3 gene. A p53 protein lacking the proline-rich region (p53delta62-91) induces many p53-responsive genes but not PIG3. In parallel, this mutant induces growth arrest but not apoptosis. We show here that the replacement of the N-terminal (amino acids 1-80) or C-terminal (amino acids 344-393) domains of p53 with heterologous domains does not interfere with transcription from the PIG3 promoter, but these chimeras still require the proline-rich region for PIG3 activation. The p53-homolog p73beta also activated the PIG3 promoter, but in contrast to p53, the proline-rich domain of p73beta (residues 81-113) was dispensable to induce the PIG3 promoter. Some tumor-derived p53-mutants, especially M246I, retained the ability to activate transcription of mdm2 but specifically failed to induce the PIG3 promoter, thus resembling p53delta62-91. Further, p53delta62-91 and p53M246I were defective for induction of apoptosis. Finally, p53delta62-91 and p53M246I both showed reduced binding to the DNA of the PIG3 promoter and also to the DNA of the mdm2 and p21 promoters in vitro. Correspondingly, at low expression levels, p53delta62-91 and p53M246I poorly activated the mdm2 promoter when compared to wild type p53. Our results suggest that the proline-rich domain of p53 affects the ability of the central domain to bind DNA. Moreover, some tumor-derived mutations within the central DNA binding domain of p53 mimic the loss of the proline-rich domain.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10777217     DOI: 10.1038/sj.onc.1203500

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain.

Authors:  C Gaiddon; M Lokshin; J Ahn; T Zhang; C Prives
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

2.  Type D retrovirus Gag polyprotein interacts with the cytosolic chaperonin TRiC.

Authors:  S Hong; G Choi; S Park; A S Chung; E Hunter; S S Rhee
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

3.  Mouse mutants reveal that putative protein interaction sites in the p53 proline-rich domain are dispensable for tumor suppression.

Authors:  Franck Toledo; Crystal J Lee; Kurt A Krummel; Luo-Wei Rodewald; Chung-Wen Liu; Geoffrey M Wahl
Journal:  Mol Cell Biol       Date:  2006-12-11       Impact factor: 4.272

Review 4.  Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.

Authors:  Franck Toledo; Geoffrey M Wahl
Journal:  Nat Rev Cancer       Date:  2006-12       Impact factor: 60.716

5.  Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: implications for therapy.

Authors:  Christin E Petre; Sang-Hoon Sin; Dirk P Dittmer
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

6.  RIP1 maintains DNA integrity and cell proliferation by regulating PGC-1α-mediated mitochondrial oxidative phosphorylation and glycolysis.

Authors:  W Chen; Q Wang; L Bai; W Chen; X Wang; C S Tellez; S Leng; M T Padilla; T Nyunoya; S A Belinsky; Y Lin
Journal:  Cell Death Differ       Date:  2014-02-28       Impact factor: 15.828

7.  p53 Amino-terminus region (1-125) stabilizes and restores heat denatured p53 wild phenotype.

Authors:  Anuj Kumar Sharma; Amjad Ali; Rajan Gogna; Amir Kumar Singh; Uttam Pati
Journal:  PLoS One       Date:  2009-10-22       Impact factor: 3.240

8.  Modulation of microRNA processing by p53.

Authors:  Hiroshi I Suzuki; Kaoru Yamagata; Koichi Sugimoto; Takashi Iwamoto; Shigeaki Kato; Kohei Miyazono
Journal:  Nature       Date:  2009-07-23       Impact factor: 49.962

Review 9.  Genetic Modifiers of the p53 Pathway.

Authors:  Subhasree Basu; Maureen E Murphy
Journal:  Cold Spring Harb Perspect Med       Date:  2016-04-01       Impact factor: 6.915

Review 10.  p53 polymorphisms: cancer implications.

Authors:  Catherine Whibley; Paul D P Pharoah; Monica Hollstein
Journal:  Nat Rev Cancer       Date:  2009-02       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.